Across TCGA pan-cancer cohorts, SCGB2B2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SCGB2B2 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SCGB2B2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SCGB2B2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ACC, CESC, and SKCM are the cancer types where SCGB2B2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.195	0.748	.003	15	view →
CESC	DFS	Median	All	0.191	0.823	<.001	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.208	.010	5	view →
COAD	OS	Median	II,III,IV	0.556	0.850	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SCGB2B2 tumor-vs-normal RNA expression · all SCGB2B2 data types